Cutler Group LP Acurx Pharmaceuticals, Inc. Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
A detailed history of Cutler Group LP transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Cutler Group LP holds 1,200 shares of ACXP stock, worth $552. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,200
Previous 2,300
47.83%
Holding current value
$552
Previous $8,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACXP
# of Institutions
31Shares Held
1.42MCall Options Held
13.6KPut Options Held
4K-
Vanguard Group Inc Valley Forge, PA529KShares$243,5000.0% of portfolio
-
Prospect Financial Services LLC Melville, NY329KShares$151,3740.15% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$67,3900.0% of portfolio
-
Morgan Stanley New York, NY106KShares$48,8520.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA48.4KShares$22,2520.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $5.32M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...